F
Finerenone
Availability of ACE Drug Guidance
Yes
Biologics Drug Information Overview
No
Subsidy Information and Financing Scheme
Medical Assistance Fund
Active ingredient: Finerenone
General information
Subsidy Information and Financing Scheme
[MAF] Finerenone Tablet 10 mg, 20 mg
As an add-on therapy for adults with chronic kidney disease and albuminuria associated with type 2 diabetes:
• who are receiving concomitant optimal standard treatment which includes an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) at maximum tolerated dose in combination with a sodium-glucose co-transporter 2 (SGLTinhibitor, unless contraindicated or not tolerated, and
• who have estimated glomerular filtration rate (eGFR) ≥25 mL/min/1.73m2 and urine albumin-to-creatinine ratio (UACR) ≥200 mg/g (20 mg/mmol) at the start of treatment.
Finerenone must be initiated by, or in consultation with, a specialist physician experienced in the management of chronic kidney disease and albuminuria associated with type 2 diabetes.
Treatment with finerenone must be discontinued prior to initiating dialysis.
Drug Guidance for Subsidy
The Ministry of Health’s Drug Advisory Committee has recommended:
Finerenone 10 mg and 20 mg tablets as an add-on therapy for adults with chronic kidney disease and albuminuria associated with type 2 diabetes:
who are receiving concomitant optimal standard treatment which includes an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) at maximum tolerated dose in combination with a sodium glucose co-transporter 2 (SGLT2) inhibitor, unless contraindicated or not tolerated, and
who have estimated glomerular filtration rate (eGFR) ≥25 mL/min/1.73m2 and urine albumin-to-creatinine ratio (UACR) ≥200 mg/g (20 mg/mmol) at the start of treatment.
Funding status
[R] Finerenone 10 mg and 20 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 November 2025.
[R] Finerenone must be initiated by, or in consultation with, a specialist physician experienced in the management of chronic kidney disease and albuminuria associated with type 2 diabetes.
[R] Treatment with finerenone must be discontinued prior to initiating dialysis.
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Availability information
Formulation | Public Healthcare Institution |
|---|---|
Tablet 10 mg |
|
Tablet 20 mg |
|
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch. The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch for the most updated product information. |
Oral
* Clinical information is available for this product.